News headlines about Recro Pharma (NASDAQ:REPH) have been trending somewhat positive this week, Accern reports. The research group identifies positive and negative media coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Recro Pharma earned a news sentiment score of 0.08 on Accern’s scale. Accern also gave media stories about the specialty pharmaceutical company an impact score of 46.0605851947031 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
REPH has been the subject of several recent research reports. Oppenheimer set a $19.00 price objective on Recro Pharma and gave the company a “buy” rating in a research report on Wednesday, February 28th. ValuEngine upgraded Recro Pharma from a “sell” rating to a “hold” rating in a research report on Thursday, March 1st. Zacks Investment Research upgraded Recro Pharma from a “sell” rating to a “hold” rating in a research report on Wednesday, March 21st. UBS initiated coverage on Recro Pharma in a research report on Tuesday, February 13th. They issued an “outperform” rating for the company. Finally, CIBC initiated coverage on Recro Pharma in a research report on Wednesday, February 14th. They issued an “outperform” rating and a $19.00 price objective for the company. Three analysts have rated the stock with a hold rating and five have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $14.21.
REPH opened at $10.58 on Friday. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.55 and a current ratio of 1.75. Recro Pharma has a 52-week low of $5.81 and a 52-week high of $12.23. The company has a market cap of $208.05, a PE ratio of -5.32 and a beta of -0.74.
In related news, major shareholder Healthcare Master Fun Broadfin sold 200,000 shares of the company’s stock in a transaction on Tuesday, March 13th. The stock was sold at an average price of $10.07, for a total value of $2,014,000.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 21.60% of the stock is owned by corporate insiders.
WARNING: This story was published by BBNS and is owned by of BBNS. If you are reading this story on another publication, it was stolen and republished in violation of US and international copyright & trademark legislation. The correct version of this story can be read at https://baseballnewssource.com/2018/04/06/somewhat-positive-news-coverage-somewhat-unlikely-to-affect-recro-pharma-reph-share-price/2029543.html.
About Recro Pharma
Recro Pharma, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company’s lead product candidate is an injectable form of meloxicam.
Receive News & Ratings for Recro Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma and related companies with MarketBeat.com's FREE daily email newsletter.